A Multiple-Ascending-Dose Study of the Safety and Tolerability of REGN421(SAR153192) in Patients With Advanced Solid Malignancies

Inclusion Criteria

• •1. Male or female 18 years of age or older
• •2. Histologically diagnosis of advanced solid malignancy, with no standard therapeutic options of proven benefit.
• •3. Patients with measurable or non-measurable disease
• •4. At least 6 weeks must have elapsed since the last dose of bevacizumab (AvastinTM)
• •5. At least 4 weeks must have elapsed since the last major surgery
• •6. For women of childbearing potential, a negative urine pregnancy test at the screening visit
• •7. Willingness to use adequate contraception during the full course of the study. Systemic hormonal contraceptive agents are excluded
• •8. Willing, committed, and able to return for ALL clinic visits and complete all study-related procedures.
• •9. Able to read, understand and willing to sign the informed consent form